ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Hubei Jumpcan Pharmaceutical Co's annualizedNet Income for the quarter that ended in Mar. 2026 was ¥1,601 Mil.
Hubei Jumpcan Pharmaceutical Co's average Total Assets over the quarter that ended in Mar. 2026 was ¥17,769 Mil. Therefore, Hubei Jumpcan Pharmaceutical Co's annualized ROA % for the quarter that ended in Mar. 2026 was 9.01%.
SHSE:600566'
s ROA % Range Over the Past 10 Years
Min: 9.83 Med: 16.53 Max: 23.3
Current: 9.98
During the past 13 years, Hubei Jumpcan Pharmaceutical Co's highest ROA % was 23.30%. The lowest was 9.83%. And the median was 16.53%.
SHSE:600566's ROA % is ranked better than 83.48% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 2.72
vs SHSE:600566: 9.98
Hubei Jumpcan Pharmaceutical Co (SHSE:600566) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Hubei Jumpcan Pharmaceutical Co ROA % Related Terms
Hubei Jumpcan Pharmaceutical Co ROA % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hubei Jumpcan Pharmaceutical Co's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hubei Jumpcan Pharmaceutical Co ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hubei Jumpcan Pharmaceutical Co's ROA % distribution charts can be found below:
* The bar in red indicates where Hubei Jumpcan Pharmaceutical Co's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Hubei Jumpcan Pharmaceutical Co (SHSE:600566) has a ROA % of 9.01% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Hubei Jumpcan Pharmaceutical Co and its competitors. This is 45% below median its historical median of 16.53. Over the past decade, Hubei Jumpcan Pharmaceutical Co's ROA % has ranged from 9.83 to 23.30. According to the industry distribution chart, Hubei Jumpcan Pharmaceutical Co ranks #166 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 16.5%.
Is Hubei Jumpcan Pharmaceutical Co's ROA % too high?
Hubei Jumpcan Pharmaceutical Co's current ROA % of 9.01% is 45% below median its 10-year median of 16.53. Over the past 10 years, this metric has ranged from a low of 9.83 to a high of 23.30. The Drug Manufacturers industry median ROA % is 2.72. Hubei Jumpcan Pharmaceutical Co's value of 9.01% is 231.3% above this industry median. Based on the distribution chart, Hubei Jumpcan Pharmaceutical Co ranks #166 out of 1005 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hubei Jumpcan Pharmaceutical Co has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Hubei Jumpcan Pharmaceutical Co's ROA % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hubei Jumpcan Pharmaceutical Co ranks #166 out of 1005 companies for ROA %. This places Hubei Jumpcan Pharmaceutical Co in the top 17% of its industry — outperforming the majority of peers. The industry median ROA % is 2.72. Hubei Jumpcan Pharmaceutical Co's value of 9.01% is 231.3% above this benchmark. Historically, Hubei Jumpcan Pharmaceutical Co's own ROA % has ranged from 9.83 to 23.30 over the past decade. While the company's 10-year median is 16.53 vs. the industry median of 2.72, Hubei Jumpcan Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.72, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hubei Jumpcan Pharmaceutical Co's current ROA % of 9.01% is 231.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Hubei Jumpcan Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hubei Jumpcan Pharmaceutical Co's current ROA % is 9.01%, which is 45% below median its own 10-year median of 16.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hubei Jumpcan Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Hubei Jumpcan Pharmaceutical Co (SHSE:600566) is currently considered Fairly Valued. The stock's GF Value™ is ¥20.92, compared to a current price of ¥22.47 — trading 7.4% above its estimated fair value. The current ROA % is 9.01%, which is 45% below median its 10-year median of 16.53 and 231.3% above the Drug Manufacturers industry median of 2.72. Hubei Jumpcan Pharmaceutical Co's overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Hubei Jumpcan Pharmaceutical Co (SHSE:600566), the current ROA % is 9.01% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hubei Jumpcan Pharmaceutical Co (SHSE:600566) Overvalued in 2026?
Based on GuruFocus' analysis, Hubei Jumpcan Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥22.47 is trading 7.4% above its estimated GF Value™ of ¥20.92.
GuruFocus considers Hubei Jumpcan Pharmaceutical Co to be Fairly Valued.
Key valuation signals for SHSE:600566:
ROA %: 9.01% (45% below median its 10-year median of 16.53)
GF Value™: ¥20.92 vs. price of ¥22.47 (7.4% above fair value)
Industry Position: 231.3% above the Drug Manufacturers median (#166 of 1005)
No single metric tells the full story. See the SHSE:600566 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hubei Jumpcan Pharmaceutical Co Business Description
Hubei Jumpcan Pharmaceutical Co Ltd engages in the research, development, manufacturing, and trading of Chinese traditional medicines, western medicines, daily use chemicals based on Chinese traditional medicines, and Chinese medicine health products in China. It offers Chinese and Western medicines in the areas of pediatrics, gynecology, pneumonology, gastroenterology, and geriatrics. The company also develops Chinese and Western medicines in the areas of detoxification, digestive system, respiratory system, nervous system, anti-infection, cardiovascular, narcotic analgesic, nutrition, musculoskeletal, and hemostasis.
87GF Score
Get the complete analysis for SHSE:600566
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600566 has been successfully added to your 
